09:04 AM EST, 12/09/2024 (MT Newswires) -- Health care stocks were edging higher premarket Monday, with The Health Care Select Sector SPDR Fund ( XLV ) and the iShares Biotechnology ETF (IBB) up 0.1%.

Arcellx ( ACLX ) shares were up 8.6% pre-bell Monday after the company said preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.

Agios Pharmaceuticals ( AGIO ) shares were down 7.5% even after the company said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.

Beam Therapeutics ( BEAM ) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model. Beam shares were up 6.6% pre-bell Monday.